The US Department of Labor’s (DOL) Employee Benefits Security Administration (EBSA) has finalized a significant new rule requiring pharmacy benefit managers (PBMs) to disclose detailed information about their compensation, pharmacy reimbursement arrangements, and other financial practices to fiduciaries of certain employer-sponsored health plans. The rule represents an important development for pharmacies that have long raised concerns about below-cost reimbursement, opaque PBM pricing practices, retroactive payment adjustments, and the growing influence of PBM–affiliated pharmacies.
For independent pharmacies, the rule could have meaningful implications for PBM contracting, reimbursement transparency, audit activity, and pharmacy network arrangements. Although the rule places the disclosure obligations primarily on PBMs and other covered service providers, pharmacies should anticipate increased requests for information and greater scrutiny of their existing PBM agreements.
The rule applies to PBMs serving certain large, self-insured group health plans regulated by the Employee Retirement Income Security Act of 1974 (ERISA). Importantly, these plans have historically been outside the reach of many state-level PBM reforms applicable to fully insured plans, making the federal rule an important additional source of transparency and oversight in the pharmacy benefits marketplace.
Key Pharmacy Impacts
Pharmacy Reimbursement and PBM Spread Pricing Will Become More Transparent.
PBMs must disclose, on a drug-by-drug basis, the contracted compensation paid by a covered plan and the amount paid to the dispensing pharmacy, along with the resulting cost spread. These disclosures must identify drugs by National Drug Code (NDC) and distinguish between retail, mail-order, and specialty channels.
For pharmacies, this is significant because it provides plan fiduciaries with information that may help identify differences between what a PBM receives from a health plan and what the PBM pays the pharmacy. Greater visibility into these arrangements could strengthen plan sponsors’ ability to question reimbursement methodologies and evaluate PBM contract terms.
For pharmacies, although the rule does not guarantee improved reimbursement, greater transparency could create additional pressure on PBMs to explain and justify their payment arrangements.
PBM Recoupment and Retroactive Reimbursement Practices Will Be Exposed.
PBMs must report both the expected and actual copay clawbacks and other retroactive adjustments to pharmacy reimbursement, including the number of transactions involved.
These disclosures expressly encompass practices such as effective-rate reconciliations and similar post-adjudication adjustments through which PBMs may recoup amounts previously paid to pharmacies. This is important to pharmacies that experience unexpected reimbursement reductions or retroactive adjustments that can materially affect cash flow and profitability. The increased visibility contemplated by the rule may make it more difficult for PBMs to rely on broadly worded contractual provisions without explaining the financial consequences of those provisions.
PBM–Affiliated Pharmacy Arrangements and Patient Steering Will Receive Greater Scrutiny.
PBMs must describe contract terms, incentives, and policies that steer patients toward PBM–affiliated pharmacies.
This requirement could bring increased attention to restrictive pharmacy networks, preferred-pharmacy arrangements, mandatory mail-order programs, and specialty pharmacy referral requirements. For independent pharmacies, greater transparency may provide plan fiduciaries with additional information to evaluate whether network design and patient-steering practices are reasonable and aligned with plan and participant interests.
Disclosures concerning financial incentives and affiliated-pharmacy arrangements may help plan fiduciaries and government regulators better understand whether network and referral decisions are driven by patient access and plan costs or by financial arrangements that benefit affiliated entities. For independent pharmacies, this creates an opportunity to bring greater attention to the competitive consequences of patient-steering practices, including the impact of preferred networks and mandatory specialty or mail-order arrangements on independent pharmacy participation and patient choice.
PBM Contracts and PBM Disclosures May Be Subject to Annual Audits.
Covered plans have the right to audit PBM disclosures at least once annually. PBMs must furnish relevant records, claims, transaction-level data, and other information reasonably necessary to verify disclosures, including contracts with pharmacies, drug manufacturers, and rebate aggregators.
The final rule also provides that covered plans select their own auditors and that PBMs cannot impose limitations on auditor selection. PBMs generally must provide requested audit information within 60 days, absent extraordinary circumstances beyond their control. Reasonable confidentiality protections are permitted.
Although the audit right belongs to the covered plan and is directed at the PBM’s disclosures, pharmacy contracts and pharmacy-related transaction data may become part of the audit process. Pharmacies should be prepared for increased requests for contractual information, reimbursement data, and cooperation with PBM or plan-related inquiries.
Pharmacy Agreements and Data-Sharing Obligations May Need to Be Updated.
As PBMs work to comply with the new disclosure and audit requirements, pharmacies may encounter requests to amend existing agreements or execute additional documentation addressing data access, confidentiality, reimbursement reporting, and audit cooperation.
PBM Compensation From Drug Manufactures and Other Sources Will Receive Greater Transparency.
The rule requires disclosure of rebates, fees, alternative discounts, and other remuneration that PBMs, their affiliates, agents, or subcontractors receive from drug manufacturers, distributors, wholesalers, and rebate aggregators. These disclosures are intended to provide plan fiduciaries with a more complete understanding of the financial arrangements and potential conflicts of interest associated with PBM services. Although these disclosures are directed to covered plans rather than pharmacies, they may influence how plan sponsors evaluate PBM pricing arrangements, negotiate contracts, and assess the overall economics of their pharmacy benefit programs.
Pharmacies should carefully evaluate these requests before agreeing to expanded disclosure or cooperation obligations. Contract amendments should be reviewed to ensure that they do not unnecessarily compromise proprietary business information, create additional operational burdens, or limit the pharmacy’s existing contractual rights.
Important Limitations for Pharmacies: What the Rule Does Not Do
Although the final rule brings greater transparency, pharmacies should understand the distinction between the disclosure rights created for covered health plans and the contractual rights held by individual pharmacies.
The rule does not:
- Create a general, direct right for pharmacies to obtain the PBM disclosures provided to covered health plans.
- Require PBMs to increase pharmacy reimbursement rates or guarantee that pharmacies will receive the same amounts paid by health plans.
- Prohibit spread pricing, retroactive reimbursement adjustments, or PBM–affiliated pharmacy arrangements.
- Automatically modify existing PBM–pharmacy contracts or eliminate existing contractual recoupment provisions.
The rule creates a framework through which covered plan fiduciaries can obtain and verify additional information about PBM compensation and financial arrangements. The resulting scrutiny may indirectly benefit pharmacies by increasing pressure on PBMs to explain their practices and potentially reconsider certain contractual and reimbursement arrangements.
Pharmacies should not assume that the new rule independently provides a basis to demand additional reimbursement or access information that is not otherwise available under their contracts or applicable law. Pharmacies should evaluate how the rule may affect their existing contractual rights and identify opportunities to use the increased transparency to support future negotiations and reimbursement discussions.
What Pharmacies Need to Do Next
Although pharmacies are not the primary entities responsible for making disclosures under this rule, proactive preparation is important. Pharmacy owners and operators should consider the following steps:
- Inventory Your PBM Agreements. Review current PBM contracts for reimbursement provisions, retroactive adjustments, effective-rate reconciliations, recoupment rights, data-sharing obligations, confidentiality restrictions, audit provisions, and network-participation requirements. Identify provisions that may need clarification or modification in light of the new disclosure requirements.
- Review Proposed Contract Amendments Carefully. Do not assume that new PBM disclosure requirements automatically justify expanded PBM access to pharmacy records or changes to existing reimbursement and recoupment rights. Evaluate proposed amendments to ensure that the pharmacy’s contractual and business interests remain protected.
- Obtain Compliance and Legal Guidance. Work with legal counsel experienced in pharmacy operations, PBM contracting, and state and federal pharmacy regulations to evaluate the potential impact of the rule, review existing agreements, and prepare for anticipated changes in PBM contracting and compliance practices.
- Document Reimbursement and Recoupment Practices. Maintain records of reimbursement disputes, retroactive adjustments, copay clawbacks, effective-rate reconciliations, and other PBM–payment adjustments. Organized documentation can help pharmacies evaluate PBM practices, respond to information requests, and identify potential contractual issues.
- Prepare for Data and Documentation Requests. Ensure that pharmacy reimbursement records, claims information, transaction histories, and relevant PBM agreements are organized and accessible. Establish procedures for responding to reasonable information requests while protecting confidential and proprietary business information.
- Evaluate Opportunities to Leverage Increased Transparency in PBM Negotiations. Pharmacies should consider how the information disclosed under the rule could affect the negotiating position of employer-sponsored health plans and, indirectly, the terms offered to participating pharmacies. Increased visibility into PBM compensation, pharmacy reimbursement, and affiliated-pharmacy arrangements may create additional opportunities to challenge unfavorable reimbursement structures and seek more transparent contractual terms.
Effective Date and Applicability
The final rule was published in the Federal Register on November 2, 2026, and becomes effective January 4, 2027. Its requirements apply to plan years beginning on or after July 1, 2027.i The final rule applies to PBMs and other covered service providers providing pharmacy benefit management services to certain large, self-insured group health plans subject to ERISA. It also addresses affiliated providers of brokerage and consulting services that meet the appliable definition of a covered service provider. Accordingly, pharmacies should begin reviewing their PBM agreements and internal documentation well in advance of the applicability date.
How Barclay Damon Can Help
The DOL’s new PBM Transparency Rule is an important development for pharmacies navigating an increasingly complex regulatory and reimbursement environment. While the rule is intended to provide greater transparency to employer-sponsored health plans, its practical effects may extend to pharmacy contracts, reimbursement arrangements, data-sharing practices, and PBM–pharmacy relationships more broadly.
Barclay Damon’s national Pharmacy Team works with pharmacies on the legal and business challenges affecting today’s pharmacy industry. We are closely monitoring developments in PBM regulation and will continue to provide guidance as implementation of the new rule progresses. Our attorneys are prepared to answer your questions and provide guidance about how the new Transparency Rule may affect your pharmacy or practice, including assistance reviewing and negotiating PBM agreements and preparing for compliance and documentation requests.
If you have any questions regarding the content of this alert, please contact Brad Gallagher or Linda Clark, Pharmacy Team co-leaders, at bgallagher@barclaydamon.com and lclark@barclaydamon.com; Rachael Judge, law clerk, at rjudge@barclaydamon.com; or another member of the firm’s Pharmacy Team.
iDOL, Final Rule, proposed 29 C.F.R. § 2550.408b-22.